Arab and Banerjee address how the population and inclusion criteria for MAESTRO compare to that of real-world populations with MASH. Arab notes a substantial proportion of patients in the MAestRO study had advanced fibrosis (F3 or higher), which may influence the perspectives of clinicians entering the field. Banerje suggests focusing on patients with higher fibroses scores (F2 or F3) as they are at greater risk of adverse outcomes and may derive the most benefit from treatment.